摘要
目的筛选和鉴定人工合成的人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞预测表位。方法对预测的E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞(CTL)表位运用标准Fmoc方案进行合成与纯化,采用标准51Cr释放试验检测特异性CTL诱导活性。结果筛选并鉴定出E711-19(YMLDLQPET)和E749-57(RAHYNIVTF)2条人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性CTL表位。结论E711-19(YMLDLQPET)和E749-57(RAHYNIVTF)抗原性较强,有可能作为HPV感染治疗用肽疫苗的候选表位。
Objective To screen and identify the predicted epitopes of synthesized predicted HLA-A2-restricted cytotoxic T lymphocytes (CTLs) derived from HPV16 E7 antigen. Methods The predicted epitopes of HLA-A2-restricted CTLs derived from HPV16 E7 antigen were synthesized and purified with Standard Fmoc assays, and the standard 51Cr release assay was used to determine their activities to induce specific CTL. Results Two epitopes of HLA-A2-restricted CTLs, namely E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) derived from HPV16 E7 antigen were identified. Conclusion E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) have antigenicity, and may be the candidates for development of peptide vaccine in the treatment of HPV infections.
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2004年第5期283-284,共2页
Chinese Journal of Dermatology
基金
国家自然科学基金(30070698)
